Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aurora Biosciences (ABSC) -- Ignore unavailable to you. Want to Upgrade?

To: THE LEPRECHAUN who wrote (170)	11/5/1998 8:53:00 PM
From: Richard Haugland	Respond to of 359

Acadia Pharma (San Diego version at least) ACADIA Pharmaceuticals ACADIA Pharmaceuticals 3911 Sorrento Valley Blvd. San Diego, CA 92121 Primary Contact: Michael K. Dunn, Ph.D. Manager of Business Development Tel: 619-558-2871 Fax: 619-558-2872 About ACADIA Pharmaceuticals: ACADIA Pharmaceuticals is an integrated drug discovery company engaged in the identification of novel lead compounds for pharmaceutical development. ACADIA has developed a platform of proprietary breakthrough technologies for rapid analysis of genomic function, including the patented Receptor Selection and Amplification Technology (R-SATô). ACADIA's technology allows the Company to exploit the paradigm shift occurring in the pharmaceutical industry,whereby novel drug targets are increasingly identified through genomic initiatives. The Company's innovative discovery platform combines the efficient enablement of gene-based assays with ultra high-throughput screening and clinically relevant pharmacology. Together with ACADIA's expertise in medicinal chemistry, R-SATô dramatically reduces the time required for discovery of lead compounds and is expected to facilitate the timely development of therapeutics in a variety of important disease areas. Using R-SAT, the Company has already identified lead compounds targeting adrenergic and muscarinic receptor subtypes. Preclinical programs in Attention Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's Disease (AD) have been established to enhance the value of these compounds. The Company has several discovery programs in various stages, as well as a technology development initiative to achieve functional testing of the majority of targets encoded by the human genome. In addition to accelerating internal discovery efforts, this platform is anticipated to have broad applications in compound profiling and pharmacogenomics. ABSC showed at least some life today although the MM got all the sales at 4 3/4, bypassing my sell orders just below that.

To: THE LEPRECHAUN who wrote (170)	11/19/1998 11:32:00 PM
From: Richard Haugland	Read Replies (1) \| Respond to of 359

Acacia not Acadia Sorry that your spelling led me to the wrong company. You apparently mean Acacia, which is the company with which ABSC recently settled a suit on GFP through a crosslicense. biz.yahoo.com Acacia is in Richmond CA and must have a terrible time being distinguished from Acadia, which is in San Diego. Now I don't know where Copenhagen comes in but maybe there is someone else yet, although I doubt it.